Lexaria Bioscience Corp LEXX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 15, 2024 (filed on Mar 15, 2024)

Insider Name:

Cabatuan Nelson

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Oct 26, 2023 (filed on Nov 01, 2023)

Insider Name:

Carle Vanessa

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Oct 26, 2023 (filed on Oct 30, 2023)

Insider Name:

Docherty John Martin

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

30,000

Price:

--
Oct 26, 2023 (filed on Oct 30, 2023)

Insider Name:

Bunka Christopher

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

30,000

Price:

--
Jul 25, 2023 (filed on Jul 25, 2023)

Insider Name:

Baxter Nicholas W

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,000

Price:

--
Jul 25, 2023 (filed on Jul 25, 2023)

Insider Name:

McKechnie William Edward

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,000

Price:

--
Jul 25, 2023 (filed on Jul 25, 2023)

Insider Name:

Reese Albert L Jr

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,000

Price:

--
Jul 25, 2023 (filed on Jul 25, 2023)

Insider Name:

Turkel Catherine C.

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,000

Price:

--

Filings by filing date

Mar 15, 2024 (filed on Mar 15, 2024)

Insider Name:

Cabatuan Nelson

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Oct 26, 2023 (filed on Nov 01, 2023)

Insider Name:

Carle Vanessa

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Oct 26, 2023 (filed on Oct 30, 2023)

Insider Name:

Docherty John Martin

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

30,000

Price:

--
Oct 26, 2023 (filed on Oct 30, 2023)

Insider Name:

Bunka Christopher

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

30,000

Price:

--
Jul 25, 2023 (filed on Jul 25, 2023)

Insider Name:

Baxter Nicholas W

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,000

Price:

--
Jul 25, 2023 (filed on Jul 25, 2023)

Insider Name:

McKechnie William Edward

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,000

Price:

--
Jul 25, 2023 (filed on Jul 25, 2023)

Insider Name:

Reese Albert L Jr

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,000

Price:

--
Jul 25, 2023 (filed on Jul 25, 2023)

Insider Name:

Turkel Catherine C.

Ownership Type:

Direct Ownership

Securities:

Stock Options

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	100 - 740 MCCURDY ROAD KELOWNA BC V1X 2P7
Tel:	N/A
Website:	https://www.lexariabioscience.com
IR:	See website

Key People

Christopher A. Bunka Chairman of the Board, Chief Executive Officer	John Martin Docherty President, Director	Nelson D. Cabatuan Chief Financial Officer

Business Overview

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company's patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Financial Overview

For the six months ended 29 February 2024, Lexaria Bioscience Corp revenues increased from $118K to $296K. Net loss decreased 40% to $1.8M. Revenues reflect IP Licensing segment increase from $17K to $290K, B2B Product segment increase from $1K to $5K. Lower net loss reflects Research and development decrease of 46% to $820K (expense), General and administrative decrease of 20% to $1.3M (expense).

Employees:	5 as of Aug 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$24.07M as of Feb 29, 2024
Annual revenue (TTM):	$0.40M as of Feb 29, 2024
EBITDA (TTM):	-$5.23M as of Feb 29, 2024
Net annual income (TTM):	-$5.44M as of Feb 29, 2024
Free cash flow (TTM):	-$5.41M as of Feb 29, 2024
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	12,885,673 as of Apr 9, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization